NeoGenomics Introduces c-MET CDx Assay for Advanced NSCLC Treatment Guidance

FORT MYERS, Fla.--NeoGenomics, Inc., a prominent entity in oncology diagnostics, has recently made public the commercial availability of their c-MET CDx assay for non-small cell lung cancer (NSCLC). This companion diagnostic immunohistochemistry (IHC) test is now accessible to oncologists and pathologists across the nation, promising to aid in the selection of appropriate treatments for patients with advanced stages of NSCLC. Notably, the test boasts a rapid turnaround time of just 48 hours.

The c-MET CDx assay targets the detection of c-Met protein overexpression, a significant biomarker present in up to half of the patients suffering from advanced NSCLC. This development is particularly crucial as it assists in identifying patients who might be suitable for newly sanctioned targeted therapies, such as EMRELIS™ (telisotuzumab vedotin-tllv), a therapeutic agent recently endorsed by the U.S. Food and Drug Administration (FDA).

Dr. Nathan Montgomery, Vice President of Medical Services at NeoGenomics, emphasized the importance of accurate and timely biomarker assessment. "In lung cancer therapy, where targeted treatments can radically alter patient outcomes, such testing is indispensable," said Dr. Montgomery. He further highlighted that the c-MET CDx assay enriches their testing repertoire, enabling oncologists to swiftly pinpoint patients who could benefit from MET-directed therapies. This tool also complements NeoGenomics’ PanTracer™ suite, which offers comprehensive biomarker profiling for NSCLC.

Key attributes of NeoGenomics' newly launched assay include:

- **Companion Diagnostic Indication**: It is developed following FDA guidelines and validated for applications involving MET-targeted therapies.
- **Rapid Turnaround**: It promises to deliver results within 48 hours, facilitating timely and well-informed clinical decisions.
- **Validated Performance**: Tailored for use with tumor tissue samples to detect excess MET protein expression.
- **Integrated NSCLC Offering**: It augments NeoGenomics' extensive PanTracer™ portfolio, which covers genomic and immuno-oncology markers.

The inclusion of the c-MET CDx assay in NeoGenomics' wide-ranging NSCLC testing offerings signifies a step forward in precision cancer care. It supports the expanding utilization of MET-directed therapies and demonstrates a commitment to aligning diagnostic services with the evolving standards in cancer treatment.

NeoGenomics, Inc., renowned for its specialization in cancer genetics diagnostics and information services, offers one of the most exhaustive oncology-focused testing menus. The company supports oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms in diagnosing and treating cancer. Based in Fort Myers, Florida, NeoGenomics operates a network of laboratories accredited by the College of American Pathologists (CAP) and certified under the Clinical Laboratory Improvement Amendments (CLIA) for comprehensive sample processing and analysis across the United States. Additionally, it maintains a full-service sample processing laboratory in Cambridge, United Kingdom, also accredited by CAP.

This strategic advancement in NeoGenomics’ service offerings underscores its dedication to enhancing precision oncology through innovative diagnostic tools and services designed to meet the needs of the healthcare community in managing complex cancer cases.